Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bio Rad Laboratories Inc BIO

Alternate Symbol(s):  BIO.B

Technology Scientific & Technical Instruments
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and... see more

Recent & Breaking News (NYSE:BIO)

BlueRock Therapeutics Announces First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson's Disease

PR Newswire June 8, 2021

bioSyntagma Launches First Multi-Omic Spatial Platform for Clinical Applications

PR Newswire June 8, 2021

BerGenBio Receives FDA Fast Track Designation For Bemcentinib / Anti-PD-(L)1 Combination In NSCLC

PR Newswire June 8, 2021

Innovent Biologics and IASO Biotherapeutics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress

PR Newswire June 7, 2021

Live from ASCO 2021 | Ascentage Pharma Presents Updated Results of MDM2-p53 Inhibitor Alrizomadlin (APG-115) Demonstrating an ORR of 24.1% Including Complete Response in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant or Refractory to Prior Immuno-Oncologic Drugs

PR Newswire June 7, 2021

FDA Approval of Aducanumab

PR Newswire June 7, 2021

Fusion Pharmaceuticals Appoints Isabelle Dussault, Ph.D. as Senior Vice President, Research

Canada NewsWire June 7, 2021

Hawaii Biotech President And CEO Elliot Parks Stepping Down

PR Newswire June 7, 2021

GenesisCare Appoints Two New U.S Chief Medical Officers

PR Newswire June 7, 2021

Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ

PR Newswire June 7, 2021

Quantgene Demonstrates Game-Changing Sequencing Precision In GENES, A Leading Scientific Journal

PR Newswire June 7, 2021

FDA Grants Accelerated Approval for Alzheimer's Drug

PR Newswire June 7, 2021

Synaptogenix Responds to FDA Approval of Aducanumab

PR Newswire June 7, 2021

CAPTIVATE Study Shows an IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)

PR Newswire June 7, 2021

Kimberly-Clark Partners with Biotech Innovator RWDC to Design Sustainable Alternatives to Traditional Plastics

PR Newswire June 7, 2021

ObvioHealth announces a groundbreaking partnership with Dedalus Group to unite real world & clinical trial data

PR Newswire June 7, 2021

Swift Biosciences launches Swift 2S(TM) Turbo v2 for metagenomic research

PR Newswire June 7, 2021

Company Set to Transform Cancer Patients' Lives Pitches for Funding on New Business Series Unicorn Hunters

PR Newswire June 7, 2021

Linnaeus Therapeutics Announces Presentation of Positive Phase 1 Clinical Data of LNS8801 at 2021 ASCO Annual Meeting

PR Newswire June 7, 2021

23andMe COVID-19 Study Finds Genetic Link to Loss of Smell Among COVID-19 patients

PR Newswire June 7, 2021